Table 1 Ongoing studies in relapsed/refractory peripheral T-cell lymphoma
NCT number | Study Title | Interventions | phase | Country | drug target |
|---|---|---|---|---|---|
NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | Biological: lacutamab | Phase 1 | multinational | anti-KIR3DL2 monoclonal antibody |
NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | Drug: CPI-818 | Phase 1 | multinational | irreversible Interleukin-2-Inducible T-Cell Kinase (ITK) inhibitor |
NCT04447027 | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | Drug: Romidepsin Drug: Lenalidomide Drug: CC-486 (5-azacitidine) Drug: Dexamethasone | Phase 1 | United State | DNA methyltransferase (DNMT) inhibitors |
NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma | Combination Product: Pembrolizumab administered using the Sofusa® DoseConnect™ | Phase 1 | United State | anti-PD1 antibody |
NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Drug: Tinostamustine | Phase 1 | multinational | alkylating deacetylase inhibitor |
NCT05079282 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Drug: ONO-4685 | Phase 1 | United States | anti-PD-1/CD3 bispecific antibody |
NCT05290155 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | Drug: anti-CD7 CAR-T cells | Phase 1 | China | anti-CD7 CAR-T cells |
NCT04774068 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | Drug: Parsaclisib Drug: Romidepsin | Phase 1 | United States | PI3Kdelta inhibitor |
NCT05403450 | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) | Drug: Tolinapant Drug: Decitabine + Cedazuridine | Phase 1 Phase 2 | China | inhibitors of apoptosis proteins |
NCT05441761 | Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL | Drug: liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin | Phase 1 Phase 2 | China | liposomal mitoxantrone hydrochloride |
NCT05269940 | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancie | Drug: ZX-101A | Phase 1 Phase 2 | China | PI3Kδ/γ dual target inhibitor |
NCT05463263 | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Drug: STP938 | Phase 1 Phase 2 | multinational | cytidine triphosphate synthase 1 (CTPS1) inhibitor |
NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma | Biological: HSP-CAR30 | Phase 1 Phase 2 | Spain | anti-CD30 CAR-T cells |
NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | Drug: Azacitidine Injection Drug: Dasatinib Drug: Linperlisib Drug: Tucidinostat Drug: SHR2554 Drug: Camrelizumab Drug: Apatin | Phase 1 Phase 2 | China | therapies guided by molecular subtypes |
NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Biological: Durvalumab Drug: Lenalidomide Other: Laboratory Biomarker Analysis | Phase 1 Phase 2 | United State | anti-PD1 antibody |
NCT05138458 | A Study of MT-101 in Subjects With CD5 + Relapsed/Refractory TCL (IMAGINE) | Biological: MT-101 Other: MT-101 + Conditioning (Lymphodepleting) Chemotherapy | Phase 1 Phase 2 | United States | anti-CD5 CAR-T cells |
NCT05627856 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | Drug: GNC-038 | Phase 1 Phase 2 | China | tetraspecific antibody that binds four tumor-associated targets—CD3, 4-1BB, PD-L1 and CD19 |
NCT05182957 | Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma | Drug: Anti-PD-1 monoclonal antibody Drug: Lenalidomide Drug: Azacitidine | Phase 2 | China | anti-PD-1 monoclonal antibody |
NCT05140382 | AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL | Drug: AZD4573 | Phase 2 | multinational | CDK9 inhibitor |
NCT04512534 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma | Drug: PD-1 antibody + HDAC inhibitor | Phase 2 | China | PD-1 antibody + HDAC inhibitor |
NCT04329130 | Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Drug: Chidamide, Lenalidomide | Phase 2 | China | HDAC inhibitor |
NCT04083495 | CD30 CAR for Relapsed/Refractory CD30 + T Cell Lymphoma | Biological: ATLCAR.CD30 T cells Drug: Fludarabine Drug: Bendamustine Drug: Cyclophosphamide | Phase 2 | United State | anti-CD30 CAR-T cells |
NCT05495100 | A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma | Drug: Mitoxantrone liposome、Chidamide、Azacitidine | Phase 2 | China | Mitoxantrone liposome |
NCT04105010 | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Drug: AZD4205 | Phase 2 | China | Oral Janus Kinase inhibitor |
NCT05313243 | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | Drug: Brentuximab vedotin Drug: Pembrolizumab | Phase 2 | United State | anti-CD30 monoclonal antibody, anti-PD-1 monoclonal antibody |
NCT04984837 | Study of Lacutamab in Peripheral T-cell Lymphoma | Drug: Lacutamab Drug: Gemcitabine Drug: Oxaliplatine | Phase 2 | multinational | anti-KIR3DL2 monoclonal antibody |
NCT02588651 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (< 10%) Mature T Cell Lymphoma (TCL) | Drug: Brentuximab vedotin | Phase 2 | United State | anti-CD30 monoclonal antibody |
NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | Drug: CPI 613 Drug: Bendamustine | Phase 2 | United States | a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH) |
NCT05059912 | CD7 CAR T-cell for R/R CD7 + T Cell Lymphoma | Biological: Humanized CD7 CAR-T cells | Phase 2 | China | anti-CD7 CAR-T cells |
NCT04763616 | Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (ICING) | Drug: Isatuximab Drug: Cemiplimab | Phase 2 | Korea | anti-CD38 monoclonal antibody, PD-1 antibod |
NCT04296786 | Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study | Drug: Sintilimab Drug: Chidamide | Phase 2 | China | PD-1 antibod |
NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | Drug: IMC-001 | Phase 2 | Korea, | PD-1 antibod |